<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03152396</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00072858</org_study_id>
    <nct_id>NCT03152396</nct_id>
  </id_info>
  <brief_title>Pharmacist CVD Intervention for Patients With Inflammatory Arthritis</brief_title>
  <acronym>RxIALTA</acronym>
  <official_title>RxIALTA: Pharmacist CVD Intervention for Patients With Inflammatory Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Epidemiology Coordinating and Research Centre, Canada</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Epidemiology Coordinating and Research Centre, Canada</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiovascular disease (CVD) (disease of the heart and blood vessels) is one of the leading&#xD;
      causes of death and disability in Canada today. The majority of CVD cases are caused by&#xD;
      factors that can be controlled. These factors include tobacco use, obesity, high blood&#xD;
      pressure, high cholesterol, diabetes, and physical inactivity. Such factors are common and&#xD;
      not well controlled. Inflammatory arthritis (IA) (Inflammation of the joints and other&#xD;
      tissues) is considered another risk factor or CVD. As such, people who have IA and any of the&#xD;
      previously mentioned risk factors would be at high risk for developing CVD. Controlling these&#xD;
      factors will bring down the risk of having cardiovascular disease and make the quality of the&#xD;
      individuals' life better. Pharmacists work with patients and their family doctors to provide&#xD;
      cardiovascular care. Having a pharmacist involved in the care process may help patients with&#xD;
      IA reduce their CV risk. Pharmacists are easier to reach and may have more opportunities to&#xD;
      educate people about medications. This might lead to better prevention and control of&#xD;
      cardiovascular diseases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiovascular disease (CVD) is one of the leading causes of morbidity and mortality&#xD;
      worldwide and in Canada accounting for nearly one third of the total deaths in both&#xD;
      instances.1-2 The majority of CVD cases are caused by modifiable risk factors such as tobacco&#xD;
      use, obesity, hypertension, hyperlipidemia, diabetes and physical inactivity.3 Inflammatory&#xD;
      arthritis, inclusive of rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing&#xD;
      spondylitis (AS), is also recognized as an independent risk factor for CVD.4-7&#xD;
&#xD;
      It has been reported that the risk of myocardial infarction (MI), heart failure (HF) and CV&#xD;
      death among patients with IA is 2-3-fold greater than in the general population.8-10 This&#xD;
      increased CV risk reflects the combined impact of systemic inflammation, burden of&#xD;
      traditional CVD risk factors and impact of certain medications (e.g. steroids, non-steroidal&#xD;
      anti-inflammatories [NSAIDs]).5,6 An elevated risk of CVD can be identified early after IA&#xD;
      diagnosis, emphasizing the need for early efforts in CV risk screening.11&#xD;
&#xD;
      Despite being recommended by international IA management guidelines,7 CV risk assessment has&#xD;
      not been incorporated into clinicians' daily routine.7 Indeed, it has been reported that such&#xD;
      assessments generally only exist in larger centers for non-rheumatology patients.12-14&#xD;
      Moreover, Keeling and colleagues reported that most rheumatologists, who are the main care&#xD;
      givers for IA patients, conducted suboptimal CV risk assessments. 15 This gap in care for&#xD;
      patients with IA is not consistently absorbed by family physicians due to lack of recognition&#xD;
      of CV risk in these patients and competing demands of other healthcare needs (e.g. other&#xD;
      chronic diseases, cancer, diabetes). 7&#xD;
&#xD;
      Special considerations need to be taken into account when calculating CV risk in patients&#xD;
      with IA, as the 'classic' risk engines (such as Framingham16) might underestimate the overall&#xD;
      risk,17 since they have not been adequately evaluated in this patient population.18,5 For&#xD;
      example, IA patients who might benefit from lipid-lowering agents may be categorized &quot;low&#xD;
      risk&quot; when using the Framingham risk engine.17 As such it has been recommended to use a&#xD;
      modified Framingham risk engine (multiply the overall risk with 1.5) in patients with IA. 19&#xD;
&#xD;
      CV risk screening and management in patients with IA takes time and effort, but can be&#xD;
      performed by other trained health professionals. As such, it has been recommended to utilize&#xD;
      a multidisciplinary approach (integration of rheumatology, cardiology and primary care) to&#xD;
      support the care of IA patients.6,20-23 Pharmacists are front line, accessible, primary&#xD;
      healthcare professionals who see patients more frequently than any other healthcare&#xD;
      provider.24 The efficacy of their interventions in managing chronic diseases including&#xD;
      osteoarthritis,25, diabetes,7, 26 dyslipidemia,27 hypertension,28,29 heart failure,30 and CVD&#xD;
      31-34 has been well demonstrated in the literature. Pharmacists can systematically identify&#xD;
      patients at high risk of CVD,35 improve their medication use,36 and help them achieve their&#xD;
      treatment targets.27,28 In addition to clinical outcomes, pharmacist involvement in patient&#xD;
      care is associated with improved patient satisfaction and adherence to therapy.28,35,36 This&#xD;
      evidence, coupled with their advanced scope of practice, ideally position pharmacists to&#xD;
      conduct CV risk screening and management. In addition, Canadian pharmacists have access to&#xD;
      practice guidelines for management and prevention of cardiovascular disease in the general&#xD;
      population.37 They also have access to the RxEACH CV risk calculator, an interactive CV&#xD;
      screening and management tool, which will help them determine CV risk, simply communicate&#xD;
      contributing risks to patients, and show patients the impact of modifying their risks. 34&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">July 17, 2017</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>A non-randomized prospective pre-post-intervention design.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in CV risk</measure>
    <time_frame>6 months</time_frame>
    <description>CV risk re-assessment with validated RxEACH CV risk calculator</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in blood pressure</measure>
    <time_frame>6 months</time_frame>
    <description>CV risk re-assessment with validated RxEACH CV risk calculator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in LDL-cholesterol</measure>
    <time_frame>6 months</time_frame>
    <description>CV risk re-assessment with validated RxEACH CV risk calculator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in total-cholesterol</measure>
    <time_frame>6 months</time_frame>
    <description>CV risk re-assessment with validated RxEACH CV risk calculator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in HDL-cholesterol</measure>
    <time_frame>6 months</time_frame>
    <description>CV risk re-assessment with validated RxEACH CV risk calculator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in hemoglobin A1C</measure>
    <time_frame>6 months</time_frame>
    <description>CV risk re-assessment with validated RxEACH CV risk calculator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tobacco cessation</measure>
    <time_frame>6 months</time_frame>
    <description>CV risk re-assessment with validated RxEACH CV risk calculator</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Inflammatory Arthritis</condition>
  <condition>Cardiovascular Risk Factor</condition>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Ankylosing Spondylitis</condition>
  <condition>Psoriatic Arthritis</condition>
  <arm_group>
    <arm_group_label>Patients with inflammatory arthritis</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All patients enrolled have a form of inflammatory arthritis and at least one uncontrolled CV risk factor (i.e. blood pressure, LDL-cholesterol, HbA1C, or current tobacco use). Pharmacist will assess each participants CV risk score using the validated RxEACH CV risk calculator. Over the 6 month intervention period, pharmacists will assist patients to modify a contributing risk factor thru treatment recommendations, prescription adaptation, and prescribing where necessary to meet treatment targets.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CV risk assessment and modification of global risk</intervention_name>
    <description>Individualized CV risk assessment using the validated RxEACH CV risk calculator for baseline and subsequent risk assessment. Pharmacists will assist patient's to decrease CV risk over 6 months thru education, medication modification, and monthly follow-up.</description>
    <arm_group_label>Patients with inflammatory arthritis</arm_group_label>
    <other_name>prescription adaptation</other_name>
    <other_name>prescribing medications</other_name>
    <other_name>ordering lab work (eg. A1C, lipid panel)</other_name>
    <other_name>interpreting lab work (eg. A1C, lipid panel)</other_name>
    <other_name>blood pressure measurement</other_name>
    <other_name>height and weight measurements</other_name>
    <other_name>waist circumference measurement</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults (â‰¥18 years of age) who have a physician-diagnosed IA including&#xD;
&#xD;
               -  Rheumatoid arthritis&#xD;
&#xD;
               -  Psoriatic arthritis&#xD;
&#xD;
               -  Ankylosing spondylitis&#xD;
&#xD;
               -  To be eligible for inclusion, all patients must have at least one uncontrolled&#xD;
                  risk factor (i.e., blood pressure, LDL-cholesterol, HbA1c, or current tobacco&#xD;
                  use)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients will be excluded if they&#xD;
&#xD;
               -  Are unwilling to participate/sign consent form&#xD;
&#xD;
               -  Are unwilling or unable to participate in regular follow-up visits&#xD;
&#xD;
               -  Are pregnant&#xD;
&#xD;
               -  Have uncontrolled IA (i.e., during a disease exacerbation)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ross Tsuyuki, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Epidemiology Coordinating and Research Centre, Canada</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrea M Morgan, BScPharm</last_name>
    <phone>(403) 589-2576</phone>
    <email>andrea.morgan@ahs.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ross Tsuyuki, MSc</last_name>
    <phone>(403) 994-8772</phone>
    <email>rtsuyuki@ualberta.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Calgary Co-operative Association Limited</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2H 1N6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonal Ejner, BScPharm</last_name>
      <phone>(403) 219-6025</phone>
      <phone_ext>6123</phone_ext>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>May 11, 2017</study_first_submitted>
  <study_first_submitted_qc>May 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2017</study_first_posted>
  <last_update_submitted>July 25, 2017</last_update_submitted>
  <last_update_submitted_qc>July 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Epidemiology Coordinating and Research Centre, Canada</investigator_affiliation>
    <investigator_full_name>Andrea Morgan</investigator_full_name>
    <investigator_title>Research Coordinator</investigator_title>
  </responsible_party>
  <keyword>modifiable cardiovascular risk factors</keyword>
  <keyword>cardiovascular risk factors</keyword>
  <keyword>blood pressure</keyword>
  <keyword>LDL-cholesterol</keyword>
  <keyword>total-cholesterol</keyword>
  <keyword>HDL-cholesterol</keyword>
  <keyword>hemoglobin A1C</keyword>
  <keyword>tobacco cessation</keyword>
  <keyword>patient satisfaction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

